BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 24458248)

  • 1. Genetic alterations in chondrosarcomas - keys to targeted therapies?
    Samuel AM; Costa J; Lindskog DM
    Cell Oncol (Dordr); 2014 Apr; 37(2):95-105. PubMed ID: 24458248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Up-regulation of PTHrP and Bcl-2 expression characterizes the progression of osteochondroma towards peripheral chondrosarcoma and is a late event in central chondrosarcoma.
    Bovée JV; van den Broek LJ; Cleton-Jansen AM; Hogendoorn PC
    Lab Invest; 2000 Dec; 80(12):1925-34. PubMed ID: 11140704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone.
    Chen S; Fritchie K; Wei S; Ali N; Curless K; Shen T; Brini AT; Latif F; Sumathi V; Siegal GP; Cheng L
    Hum Pathol; 2017 Jul; 65():239-246. PubMed ID: 28552826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase.
    Tinoco G; Wilky BA; Paz-Mejia A; Rosenberg A; Trent JC
    Am Soc Clin Oncol Educ Book; 2015; ():e648-55. PubMed ID: 25993236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New chondrosarcoma cell lines and mouse models to study the link between chondrogenesis and chemoresistance.
    Monderer D; Luseau A; Bellec A; David E; Ponsolle S; Saiagh S; Bercegeay S; Piloquet P; Denis MG; Lodé L; Rédini F; Biger M; Heymann D; Heymann MF; Le Bot R; Gouin F; Blanchard F
    Lab Invest; 2013 Oct; 93(10):1100-14. PubMed ID: 23958880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary peripheral chondrosarcoma evolving from osteochondroma as a result of outgrowth of cells with functional EXT.
    de Andrea CE; Reijnders CM; Kroon HM; de Jong D; Hogendoorn PC; Szuhai K; Bovée JV
    Oncogene; 2012 Mar; 31(9):1095-104. PubMed ID: 21804604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel strategies for the treatment of chondrosarcomas: targeting integrins.
    Chen JC; Fong YC; Tang CH
    Biomed Res Int; 2013; 2013():396839. PubMed ID: 24490159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant heparan sulfate proteoglycan localization, despite normal exostosin, in central chondrosarcoma.
    Schrage YM; Hameetman L; Szuhai K; Cleton-Jansen AM; Taminiau AH; Hogendoorn PC; Bovée JV
    Am J Pathol; 2009 Mar; 174(3):979-88. PubMed ID: 19179614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular oncogenesis of chondrosarcoma: impact for targeted treatment.
    Speetjens FM; de Jong Y; Gelderblom H; Bovée JV
    Curr Opin Oncol; 2016 Jul; 28(4):314-22. PubMed ID: 27166664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation.
    Peterse EFP; Niessen B; Addie RD; de Jong Y; Cleven AHG; Kruisselbrink AB; van den Akker BEWM; Molenaar RJ; Cleton-Jansen AM; Bovée JVMG
    Br J Cancer; 2018 Apr; 118(8):1074-1083. PubMed ID: 29576625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of heterozygosity and DNA ploidy point to a diverging genetic mechanism in the origin of peripheral and central chondrosarcoma.
    Bovée JV; Cleton-Jansen AM; Kuipers-Dijkshoorn NJ; van den Broek LJ; Taminiau AH; Cornelisse CJ; Hogendoorn PC
    Genes Chromosomes Cancer; 1999 Nov; 26(3):237-46. PubMed ID: 10502322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma.
    Rey V; Tornín J; Alba-Linares JJ; Robledo C; Murillo D; Rodríguez A; Gallego B; Huergo C; Viera C; Braña A; Astudillo A; Heymann D; Szuhai K; Bovée JVMG; Fernández AF; Fraga MF; Alonso J; Rodríguez R
    EBioMedicine; 2024 Apr; 102():105090. PubMed ID: 38547578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IDH mutation status in a series of 88 head and neck chondrosarcomas: different profile between tumors of the skull base and tumors involving the facial skeleton and the laryngotracheal tract.
    Tallegas M; Miquelestorena-Standley É; Labit-Bouvier C; Badoual C; Francois A; Gomez-Brouchet A; Aubert S; Collin C; Tallet A; de Pinieux G
    Hum Pathol; 2019 Feb; 84():183-191. PubMed ID: 30296521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas.
    Rozeman LB; Hameetman L; Cleton-Jansen AM; Taminiau AH; Hogendoorn PC; Bovée JV
    J Pathol; 2005 Mar; 205(4):476-82. PubMed ID: 15685701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrating Morphology and Genetics in the Diagnosis of Cartilage Tumors.
    de Andrea CE; San-Julian M; Bovée JVMG
    Surg Pathol Clin; 2017 Sep; 10(3):537-552. PubMed ID: 28797501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant IDH regulates glycogen metabolism from early cartilage development to malignant chondrosarcoma formation.
    Pathmanapan S; Poon R; De Renshaw TB; Nadesan P; Nakagawa M; Seesankar GA; Ho Loe AK; Zhang HH; Guinovart JJ; Duran J; Newgard CB; Wunder JS; Alman BA
    Cell Rep; 2023 Jun; 42(6):112578. PubMed ID: 37267108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of cytofluorometric DNA ploidy analysis in distinguishing benign cartilaginous tumors from chondrosarcomas.
    Kusuzaki K; Murata H; Takeshita H; Hirata M; Hashiguchi S; Tsuji Y; Nakamura S; Ashihara T; Hirasawa Y
    Mod Pathol; 1999 Sep; 12(9):863-72. PubMed ID: 10496594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical cartilage in type II germ cell tumors of the mediastinum show significantly different patterns of IDH1/2 mutations from conventional chondrosarcoma.
    Warmke LM; Cheng L; Sperling RM; Sen JD; Ulbright TM
    Mod Pathol; 2022 Nov; 35(11):1636-1643. PubMed ID: 35660795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen signaling is active in cartilaginous tumors: implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma.
    Cleton-Jansen AM; van Beerendonk HM; Baelde HJ; Bovée JV; Karperien M; Hogendoorn PC
    Clin Cancer Res; 2005 Nov; 11(22):8028-35. PubMed ID: 16299232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma.
    Tarpey PS; Behjati S; Cooke SL; Van Loo P; Wedge DC; Pillay N; Marshall J; O'Meara S; Davies H; Nik-Zainal S; Beare D; Butler A; Gamble J; Hardy C; Hinton J; Jia MM; Jayakumar A; Jones D; Latimer C; Maddison M; Martin S; McLaren S; Menzies A; Mudie L; Raine K; Teague JW; Tubio JM; Halai D; Tirabosco R; Amary F; Campbell PJ; Stratton MR; Flanagan AM; Futreal PA
    Nat Genet; 2013 Aug; 45(8):923-6. PubMed ID: 23770606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.